Prevalence of malnutrition and nutrition‐related complications in patients with gastroenteropancreatic neuroendocrine tumours
Authors:
- 12 April 2022
- journal article
- research article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 34 (6) , e13116
Abstract
Cross‐sectional studies report that up to 25% of people with gastroenteropancreatic neuroendocrine tumours (GEP NET) are malnourished. However, the changes in nutritional status and dietary intake over time are unknown. The present study aimed to comprehensively describe the impact of a GEP NET on nutritional status and quality of life (QOL). Patients diagnosed with a GEP NET were recruited to this prospective longitudinal study on initial attendance to the NET Unit at two tertiary hospitals in Melbourne (VIC, Australia). Patient self‐reported QOL measures (European Organisation for Research and Treatment Cancer QLC‐C30 and QLC‐GINET21) and nutritional outcomes (nutritional status, weight change, fat‐free mass [FFM], dietary change, dietitian contact) were collected bi‐monthly for six months. Sixty‐one patients were recruited (66% male) with a mean ± SD age of 62 ± 12 years, predominantly diagnosed with small intestinal NET and Grade 1/2 disease. Commonly reported symptoms were fatigue (79%), abdominal discomfort (75%) and pain (68%). More patients were malnourished at baseline than at 6 months (29% vs. 13%). Over this 6 months, 48% lost weight, 20% lost ≥ 5% of their body weight, and 62% lost FFM with an average FFM loss of 2.8 kg (95% confidence interval = 2.0, 3.6), consistent with altered body composition. Dietary change was reported by 56% at baseline and 53% at six months, but only 21% consulted a dietitian at baseline and 18% at 6 months. Clinically significant loss of weight and FFM affected many patients with a GEP NET; however, few patients were referred to/or received a consultation with a dietitian. Valid screening practices are needed to identify weight loss and nutrition issues in GEP NET patients, and to facilitate referral to dietitian services.Keywords
Funding Information
- Austin Health
- Ipsen Biopharmaceuticals
- Victorian Cancer Agency
This publication has 44 references indexed in Scilit:
- Comparison of Health-Related Quality of Life in Patients With Neuroendocrine Tumors With Quality of Life in the General US PopulationPancreas, 2012
- Deficiencies in fat‐soluble vitamins in long‐term users of somatostatin analogueAlimentary Pharmacology & Therapeutics, 2010
- Nutritional intervention and quality of life in adult oncology patientsClinical Nutrition, 2007
- Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative studyHealth and Quality of Life Outcomes, 2007
- Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancerEuropean Journal of Clinical Nutrition, 2002
- Health-related Quality of Life, Anxiety and Depression in Patients with Midgut Carcinoid TumoursActa Oncologica, 2001
- Definition of standardized nutritional assessment and interventional pathways in oncologyNutrition, 1996
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Effect Sizes for Interpreting Changes in Health StatusMedical Care, 1989
- Biochemistry of tryptophan in health and diseaseMolecular Aspects of Medicine, 1983